Thursday, November 19, 2009
New warning on Plavix (from the FDA)
You've probably heard the news already. You've probably seen the FDA press release. Plavix combined with Prilosec/Prilosec OTC significantly reduces the anti-platelet efficacy of Plavix. For that matter, Plavix combined with any other drugs that inhibit the CYP2C19 enzyme will have significant drug-drug interactions.
Plavix is one of those pills that people take and we don't typically measure or monitor whether the drug is working. It's not like Coumadin (warfarin) where we constantly measure an INR to make sure that your levels are therapeutic. We don't check for peaks of troughs when you're on Plavix. However, perhaps this will change as advances in medical technology make it easier for clinicians to monitor platelet activity in cardiac patients who are taking anti-platelet therapy.
To read the recent FDA news regarding Plavix and Prilosec, click here.
Labels: cardiology, clopidogrel, drug safety, FDA, FDA Alert, Plavix
Subscribe to: Post Comments (Atom)
I rarely post, but I wanted to say thanks for sharing this information.ReplyDelete